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Summary The prognosis of patients with stage IIIB breast carcinoma with tumour spread to the apical
axillary lymph nodes has hardly improved despite adequate locoregional control and the introduction of
systemic adjuvant therapy. A combined modality regimen that includes anthracyclin-based chemotherapy, high-
dose chemotherapy with peripheral stem cell support and radiation and hormonal therapy is currently under
investigation in this subset of patients. The present study aims to document the efficacy and feasibility of dose-
intensive epidoxorubicin in combination with a standard dose of 5-fluorouracil and cyclophosphamide as up-
front chemotherapy in this setting. A preoperative chemotherapy regimen consisting of three courses of 5-
fluorouracil 500 mg m-2, epidoxorubicin 120 mg m-2 and cyclophosphamide 500 mg m-2 (FE,20C) was
administered at 21 day intervals without haematopoietic growth factors to 70 patients with apex node-positive
disease. All patients were below 60 years of age and had not had prior chemotherapy or radiotherapy. Sixty-six
patients were evaluable for clinical response and histopathological examination could be performed in 62 of
these. Thirteen patients achieved a clinical complete response (20%). Of these patients, microscopic
examination of the mastectomy specimen revealed absence of malignant cells in two and exclusively ductal
carcinoma in situ (DCIS) in another two patients. In addition, of the 46 patients (70%) with a clinical partial
response, at pathological examination one patient had sclerosis only and four had DCIS. This results in a
pathological complete response in three (5%) of all patients and absence of invasive carcinoma in 10%. None
of the patients progressed during chemotherapy. The major toxicity was moderate bone marrow suppression
with a median white blood count (WBC) nadir of 1800 pl-1 (range 500-4900). Other toxicities were mild. The
full planned dose could be given without delays in 66 of 70 patients. FE120C is well tolerated and is highly
effective as up-front chemotherapy in relatively young patients with high-risk breast cancer, with a 90% (CI
74-98%) clinical objective response rate.
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Breast cancer patients presenting with tumour spread to the
apical axillary lymph nodes, but without distant metastases,
constitute a prognostically very unfavourable subgroup of
node-positive patients. Local treatment of the primary
tumour by radiotherapy results in a 5 year survival rate of
only 21.5-40% (Borger et al., 1992; Rubens, 1978). When a
radical mastectomy is performed, a local regional recurrence
rate of 46% is reported (van Dongen, 1977). The vast
majority of breast cancer patients with apex node-positive
disease die from metastatic disease, indicating that occult
systemic metastases must have been present at the time of
first presentation. In view of these data it has been our policy
to precede a planned mastectomy with an apical axillary
lymph node biopsy (van Dongen, 1977). When tumour
involvement of the lymph node is observed on frozen
section, surgery is cancelled and the patient is scheduled for
locoregional radiation therapy. Additional systemic treatment
in patients with apex node-positive disease has been shown to
be of no benefit. In a three-armed study that we published
previously (Schaake-Koning et al., 1985), radiotherapy alone
(1) was compared with (2) radiotherapy followed by 12
courses of cyclophosphamide, methotrexate and 5-fluorour-
acil (CMF) and with (3) radiotherapy preceded and followed
by chemotherapy consisting of CMF alternated by doxor-
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ubicin and vincristine (CMF/AV) in combination with
tamoxifen. The three treatment arms led to similar results,
with relapse-free survivals ofless than 36% and 20% at 3 and
5 years respectively, and an overall survival of 60% and 40%
(Schaake-Koning et al., 1985). These results were confirmed
in two subsequent large studies, the EORTC Breast Cancer
Co-operative Group Trial 10792 (Rubens et al., 1989) and the
recent study of Perez et al. (1994) both of which showed no
significant difference in overall survival in locally advanced
breast cancer whether treated by radiotherapy alone or
followed by systemic treatment. However, based on the
number of patients that participated in these studies a small
survival advantage following conventional chemotherapy
could not be excluded.
Since it can be assumed that clinically occult metastases
are present in virtually all patients with apical axillary lymph
node-positive breast cancer at the time of diagnosis, initiation
of systemic treatment as early as possible would appear to be
logical. The biological rationale for the up-front administra-
tion of chemotherapy is based on studies on tumour cell
kinetics in mice, which have yielded substantial evidence that
surgery or radiation of a primary breast tumour resulted in
an accelerated growth of metastases induced by the release of
growth stimulating factors. The most effective control of
residual tumour cells and improvement in survival was
obtained by administration of the largest tolerable dose of
chemotherapy before removal of the primary tumour (Fisher
et al., 1983, 1989; Fisher and Mamounas, 1995).
In practice, preoperative chemotherapy has been employed
in attempts to reduce the size of large but resectable breast
cancers in order to allow breast conservation (Bonadonna et
al., 1990; Belembaogo et al., 1992; Calais et al., 1994;
Touboul et al., 1992; Mauriac et al., 1991; Perloff et al.,
1988). The majority of the preoperative chemotherapeutic
regimens contain standard doses of cyclophosphamide, 5-fluorouracil and either methotrexate or an anthracyclin. In
these studies, which comprise a heterogeneous patient
population, following up-front chemotherapy, clinical re-
sponse rates of 57-83% have been reported. However, these
high response rates have as yet not been reflected in
significant improvements in survival.
In an attempt to improve the outlook for patients with
apical node-positive stage III breast carcinoma, we have
developed a combined modality regimen incorporating
preoperative chemotherapy followed by surgery, high-dose
chemotherapy with autotransplantation, radiation therapy
and hormonal therapy (van der Wall et al., 1995) (Figure 1).
Such an approach requires a highly effective up-front
chemotherapy regimen, consisting of a small number of
courses in a short period of time, that is well tolerated by
young chemotherapy-naive patients. For this purpose, we
investigated the feasibility and efficacy of FEC with
administration of a relatively high dose of epidoxorubicin,
120 mg m-2, (FE120C). As an anthracyclin, epirubicin ranks
among the most effective agents in breast cancer and it has
been reported to have a more favourable toxicity profile than
its parent compound, doxorubicin (Italian Multicentre Breast
Study, 1988; Bonadonna et al., 1993).
As the treatment results were evaluated by different
techniques, i.e. physical examination, mammography, histo-
pathology, the study also allowed mutual comparison of their
efficacy. Haematological growth factors were not used
because repeated high-dose chemotherapy with growth
factor support could possibly compromise later attempts to
mobilise peripheral haematopoietic stem cells (Moore, 1992).
This study confirms and extends our previously published
preliminary experience with the FE120C regimen (van der
Wall et al., 1992).
Patients and methods
Patients
To be eligible for the study patients had to meet the following
criteria: histologically or cytologically documented epithelial
carcinoma of the breast with apical axillary lymph node
metastases at exploration, i.e. stage IIA-IIIB disease but
otherwise operable according to the Haagensen criteria
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(Haagensen and Stout, 1943); no evidence of distant
metastases; age below 60 years; ECOG/ZUBROD WHO
performance status 0 or 1. Renal and hepatic functions had
to be adequate, with a creatinine clearance of >60 ml min-'
and a serum bilirubin of <25 umol 1-1 respectively. Normal
bone marrow function was required with a white blood cell
count (WBC) >4.0 x 10 l- 1 and platelets > 100 x 10 l- 1 .
A history of other malignancies was not acceptable, except
adequately treated in situ carcinoma of the cervix or basal cell
carcinoma of the skin. Premenopausal status was defined by
regular menstrual cycles; patients were designated perimeno-
pausal in case of amenorrhoea for less than 1 year. All other
patients were considered to be post-menopausal.
Informed consent was obtained from all patients according
to institutional guidelines. The study was approved by the
Institutional Ethics Committee.
Pretreatment evaluation
Pretreatment evaluation included history and physical
examination, full blood count, liver function tests, serum
chemistries, creatinine clearance, urinalysis, chest radio-
graphs, mammography, radioisotope bone scan with addi-
tional radiographs when indicated, ultrasound examination of
the liver, electrocardiography (ECG) and radionuclide
cardiac ejection fraction. The histological diagnosis of
carcinoma was established by a biopsy of the apical axillary
lymph nodes.
Treatment
The preoperative chemotherapy regimen consisted of three
consecutive courses of 5-fluorouracil 500 mg m-2, epidoxor-
ubicin 120 mg m-2 and cyclophosphamide 500 mg m-2
(FE120C), administered at 3 week intervals, without haema-
topoietic growth factors. All drugs were administered by
injection in a freely running intravenous infusion. Dose
modifications were applied depending on the WBC and
platelet count at the start of each chemotherapy cycle. If the
WBC was 3000 dl-1 or less at day 21 or the platelet count
below 100 000 dl-', retreatment was delayed for a week. If
after this week recovery had occurred, a full dose of all three
agents was administered. If the WBC count was still less than
3000 til-1 but over 2000 ,ul-', a 50% dose reduction was
applied. If the WBC was even lower or if the platelet count
remained less than 100 000 ,ul-1, the patient was taken off
study.
Antiemetics were employed both prophylactically and as
needed, and consisted of 5 HT-3 antagonists with or without
dexamethasone. Patients showing progression at any time
during chemotherapy went off study to receive immediate
radiation therapy (Figure 1). In case of clinical objective
response or stable disease, a mastectomy or a tumourectomy
with axillary clearance was performed 3-4 weeks after the
third cycle. Patients considered to have clinically 'FEC-
responsive' tumours were subsequently randomised in a
second study, in which the curative potential of dose
intensification with peripheral blood progenitor cell support,
followed by surgery, radiotherapy and hormonal treatment
are investigated (Figure 1). Toxicity and efficacy data of the
high-dose chemotherapy regimen, consisting of cyclopho-
sphamide, thiotepa and carboplatin (CTC), have been
reported previously (Rodenhuis et al., 1992; van der Wall
et al., 1995).
Tamoxifen <
Figure 1 Outline of the study. FE120C, 5-fluorouracil
500mg m2, epidoxorubicin 120 mgm 2, cyclophosphamide
500mgm-2, RD, responsive disease; PD, progressive disease;
SD, stable disease; G-CSF, granulocyte colony-stimulating factor;
CTC, carboplatin, thiotepa, cyclophosphamide; PSCT, peripheral
stem cell transplantation.
Evaluation of response
The clinical response was evaluated by physical examination
of the breast and of the axilla. This was performed
independently by a surgeon and by a medical oncologist
before the first course of chemotherapy and immediately
before surgery. At the start of the second and the third cycles
of FE,20C, the medical oncologist assessed the tumour
response again. The clinical staging of the primary tumourUp-front chemotherapy with dose-intensive epidoxorubicin
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was done using the TNM classification system adopted by the
UICC (Beahrs, 1993). The sum of the product of the two
largest perpendicular diameters of all measurable lesions (e.g.
breast nodule and axillary lymph node) was calculated and
used as the parameter indicating tumour response. A partial
remission was defined as a greater than 50% reduction in size
of this sum. Less than 50% tumour reduction was reported as
stable disease. A complete response was defined as the
disappearance of all detectable lesions.
The clinical responses to chemotherapy, as judged by
physical examination, were correlated with the findings at
pathological examination of the resected specimen in order to
confirm the chemosensitivity of the primary tumour. All
specimens were reviewed by one of the authors (JLP), who
was blinded with respect to clinical response. Pathological
complete response was defined as no evidence of invasive
carcinoma or DCIS at histopathological examination of the
mastectomy specimen. The dextran-coated charcoal method
was used to define the receptor-status of the tumour
(McGuire et al., 1977).
Evaluation of toxicity
Toxicity was expressed in grades according to the WHO
criteria (Miller et al., 1981). To determine bone marrow




A total of 70 patients were entered in this study, five of
whom did not meet the entry criteria. Four patients had
undergone a mastectomy with axillary node dissection
elsewhere, at which time tumour spread to the apical lymph
nodes had been found. As a result, they were evaluable for
toxicity, but not for response. The fifth patient was
inoperable because she had inflammatory breast cancer with
multiple skin metastases. She was, however, evaluable for
toxicity as well as for clinical response, resulting in a total of
66 (94%) patients being evaluable for clinical response.
Following FE120C up-front chemotherapy, four patients
refused surgery, leaving 62 (89%) patients available for
pathological response evaluation.
Pretreatment patient characteristics are listed in Table I.
All patients had a good performance status. The median age
was 44 years and the majority of patients were premenopau-
sal (Table 1).
Clinical and pathological response (Tables II and III)
In 13 patients (20%) a clinical complete response (CR) was
observed (Table II), which was confirmed at histopathologi-
cal examination of the resected specimen in four, in which
either DCIS (n =2) or sclerosis only (n =2) was found (Table
III). In the remaining nine patients in clinical complete
response, microscopic examination of the mastectomy speci-
men revealed small areas of invasive carcinoma, which, in
one of them, was confined to two of the seven resected
axillary lymph nodes. In this patient, the mastectomy
specimen was reported to contain only DCIS (Table III).
Clinical partial responses (PR) were observed in 46
patients (70%) (Table II). At histopathological examination
one patient was found to be in complete remission, the
mastectomy specimen showing only extensive sclerosis (Table
III). In four additional patients in clinical PR, DCIS but no
invasive carcinoma was found.
Seven patients (11%) were considered to have clinical
stable disease (SD), and histopathological examination
revealed invasive carcinoma in all (Table III).
In summary, the overall clinical objective response rate
was 90%, with a 5% pathological complete remission. The
pathological complete remissions were observed in two
patients with a clinical complete remission and in one
patient who obtained a clinical partial response. In
addition, absence of invasive carcinoma, i.e. DCIS only,
was found in two patients in clinical CR and four patients in
clinical PR (Table III). Tumour progression was observed in
none of the patients during chemotherapy. Although
Table I Pretreatment patient characteristics (n = 70)
Characteristics No. ofpatients (%)













































Stage of the disease (clinical)a
Stage IIA 10 (15)
Stage IIB 17 (26)
Stage IIIA 35 (53)
Stage IIIB 4 (6)
aA total of 66 of 70 (94%) of patients were evaluable for clinical
response (see text).




tumour size CR PR SD (%)
T0a 3 1 4 (6)
T1 2 1 3 (5)
T2 5 16 - 21 (32)
T3 3 26 5 34 (52)
T4 - 2 2 4 (6)
Total (%) 13 (20) 46 (70) 7 (11) 66 (100)
aIn these patients axillary lymph nodes were the clinical evaluable
parameters.
Table III Relationship between clinical response and findings at
histopathological examination (n =62)
Pathological evaluation
Clinical Tumour Invasive DCISa
response negative carcinoma only Total (%)
Complete 2 2 13 (21)
Partial 1 37C 4 42 (68)
Stable - 7 - 7 (11)
Total (%) 3 (5) 53 (85) 6 (10) 62d (100)
aDCIS, ductal carcinoma in situ. bFollowing up-front FE120C, in
one patient the primary tumour contained only one small focus of
DCIS; however, two of the seven axillary lymph nodes showed
invasive carcinoma. cln three patients pathological examination
revealed a complete response in the breast; small foci of invasive
carcinoma were observed in the axillary lymph nodes only. dFour
patients refused surgery.clinically stable disease was observed only in the larger
tumours, there was no obvious relationship between tumour
size and clinical response (Table II). Of the T2 tumours, 24%
showed a clinical complete response compared with only 9%
of the T3 tumours but this difference is not statistically
significant. With regard to nodal status, no significant
difference was observed in patients described as either
clinically NI or N2, showing objective response rates of
90% and 83% respectively (data not shown).
In the majority of patients, one or both hormonal
receptors were found to be positive (Table I). In 17 patients
the hormonal receptor status could not be defined, however,
owing to a lack of sufficient material available for
histopathological examination, which includes the four
patients who refused surgery and those who obtained a
pathological complete remission. There was no clear relation-
ship between receptor status and response (data not shown).
While all patients showing clinical stable disease were
premenopausal, the preponderance of premenopausal pa-
tients in the studied group as a whole (Table I) excludes a
reliable judgement as to a relationship between menopausal
status and response.
Evaluation by mammography
Although, following up-front FE120C chemotherapy, a second
mammography was not routinely performed, two sequential
mammographies were available for radiological evaluation in
38 out of 66 clinically evaluable patients (58%).
In two of seven patients in clinical complete remission
available for radiological response evaluation the second
mammography confirmed the clinical findings, whereas in
both patients histopathological examination still revealed the
presence of invasive carcinoma. In the remaining five patients
in clinical CR, evaluation by mammography showed a partial
response in four cases. Histopathology reported small areas
of invasive carcinoma in all. The last patient was described as
having progressive disease on radiological examination
whereas the histopathology was in concordance with the
clinical observation, showing complete absence of malig-
nancy.
Of the patients in clinical partial remission, for whom both
mammographies were available, radiological examination
confirmed the clinical findings in eight. Of the remaining 17
patients, in 14 radiological evaluation reported stable disease.
Histopathological examination in these 22 patients showed
invasive carcinoma in all. Progressive disease on mammo-
graphy was reported in three patients in clinical PR.
Histopathology showed extensive invasive carcinoma in two
and abundant necrosis and sclerosis with a small area of
invasive carcinoma in one.
Finally, of the six radiological evaluable patients with
clinically stable disease, five showed no response on
mammography and one was described as progressive.
Invasive carcinoma was found in all.
Toxicity (n = 70)
As expected, the main toxicity of the FE120C regimen
consisted of bone marrow suppression (Table IV). In three
patients (4%) a 1 week treatment delay of the third cycle of
Table IV WBC and platelet nadirs after subsequent courses of
chemotherapy
Course of chemotherapy
Nadirs FEC, FEC2 FEC3
WBC x 106 1-' 1800 2000 2000
(900-4600) (500-4200) (500-4900)
Platelets x 109 1-, 166.000 175.000 171.000
(46-272) (48-398) (20-319)
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chemotherapy was necessary because of neutropenia. Three
patients, one of whom twice, required hospitalisation because
of neutropenic fever. Apart from a single positive culture
with a Branhamella catharalis from the sputum of one
patient, who showed no other signs of respiratory tract
infection, no positive cultures were obtained. All patients
showed a rapid recovery after intravenous administration of
antibiotics. Whereas a brief grade IV thrombocytopenia was
observed in a single patient after the third FE120C course,
platelet transfusions were not necessary (Table IV). Dose
reductions did not have to be performed in any of the
patients.
Gastrointestinal toxicity consisted mainly of nausea and
vomiting despite prophylactic antiemetic therapy. One patient
had grade IV nausea and vomiting for 3 days after the third
course whereas more than 85% of the patients experienced
grade II or less. Mucositis was mild and was grade I or less in
over 80% of the patients. The occurrence of mucositis was
equally distributed over the three courses of chemotherapy
(data not shown).
On suspicion of cardiotoxicity, a 36-year-old patient had
to be excluded from further participation in this study. Three
weeks following the first course of FE120C chemotherapy, a
15% decrease in radionuclide left ventricular ejection fraction
was reported, while at the same time her cardial history,
physical examination and the ECG were normal. One week
later, a second radionuclide scan revealed a normalised
ejection fraction, which was confirmed 1 month and 3 months
later. Although the significance of this finding was uncertain,
she was taken off study and received radiotherapy for local
control of breast cancer.
A total of 205 cycles of up-front FE120C chemotherapy
were administered, during which, in one patient, extravasa-
tion of epidoxorubicin was observed.
Finally, as expected, complete but reversible (grade III)
alopecia was observed in all patients.
Discussion
The up-front administration of FEC chemotherapy using
dose-intensive epidoxorubicin (FE120C) in 70 patients with
apex node-positive breast cancer resulted in a high objective
response rate of 90% (confidence interval 74-98%), with a
clinical complete remission in 20% of cases. Progressive
disease was not encountered.
A relationship between anthracyclin dose and response has
been reported by several investigators (Valagussa et al., 1983;
Habeshaw et al., 1991; Chevallier et al., 1993; Focan et al.,
1993) and it appears reasonable to ascribe the high objective
response rate obtained in the present study to the elevated
dose of epidoxorubicin. Recently, however, similar high rates
of clinical and pathological complete remissions were
reported following the up-front administration of a standard
dose of epidoxorubicin (50 mg m-2) in combination with
cisplatin and continuous infusion of 5-fluorouracil (5FU) in
large primary breast cancers (Smith et al., 1995). In this
study, the favourable results were ascribed to the continuous
exposure to 5FU and to the possible synergy between
cisplatin and 5FU. In general, following primary chemother-
apy response rates of 57-96% have been reported (Valagussa
et al., 1990; Chevallier et al., 1993; Bonadonna et al., 1990;
Belembaogo et al., 1992; Calais et al., 1994; Touboul et al.,
1992; Mauriac et al., 1991; Perloff et al., 1988).
Despite the high dose of epdidoxorubicin, the degree of
bone marrow toxicity was only moderate. This is certainly a
result of the fact that none of the patients had received prior
systemic treatment or radiotherapy. In addition, the patients
were relatively young and had an excellent performance
status. It cannot be excluded that continuing chemotherapy
at a 21 day interval beyond three courses would lead to some
cumulation of toxicity and that delays or dose modifications
might become less exceptional then. In the subsequent part of
the study, 3 weeks following surgery 31 patients received aUp-frorit dmindm-apy with doe-int epidoxoruicin 000 E van der Wafl et al
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fourth course of FE1_C chemotherapy followed by
granulocyte colony-stimulating factor (G-CSF) to mobilise
peripheral blood progenitor cells. No excess toxicity was
noted and high numbers of haematopoietic stem cells could
be harvested in 30 of them (van der Wall et al., 1995).
With regard to the diagnostic parameters for response
evaluation, a clear discrepancy between the reported clinical
responses and the findings at histopathological examination
of the mastectomy specimens was observed, which is in
agreement with data of other investigators (Smith et al.,
1995). In only 2 of the 13 patients in clinical complete
remission, the histopathology confirmed this response.
whereas in one patient reported to have a clinical partial
response, a pathological complete remission was observed
(Table III). In two patients in clincal CR and in four patients
in clinical PR. pathological examination disclosed the
presence of small foci of DCIS, which in former studies
have been classified as being a pathological complete
response. In the recent study of Chevallier et al. (1993), in
which patients with inflammatory breast cancer were treated
with FEC with 115 mg m-? epidoxorubicin (FEC-HD) up-
front, in half of the 25.6% patients described as having a
pathological complete response, the mastectomy specimen
contained DCIS. Therefore, while analysing the results of the
different studies that evaluate the efficacy of up-front
chemotherapy, one should carefully watch for the definition
of 'pathological complete response'.
In an additional three patients in clinical partial remission,
the mastectomy specimen showed a pathological complete
response but the axillary lymph nodes, which were not
palpable at physical examination, still contained deposits of
infiltrating carcinoma (Table III). Similar observations were
made by other investigators (Elias et al.. 1991). Thus, it
would appear that histopathological examination of the
breast and the axilla is required for an accurate estimate of
the effect of up-front chemotherapy. A palpable tumour in
the breast after chemotherapy may consist entirely of fibrosis
or may contain only carcinoma in situ.
Although the number of patients available for radiological
evaluation was small, comparison of the clinical examination
with the mammography showed disagreement in the majority
of cases, especially in patients in clinical partial remission
(data not shown). This is in contrast with the results of the
study of Moskovic et al. (1993), who reported agreement
between clinical and radiological evaluation in 79% of
patients. However, in two-thirds of these patients they
observed a difference in degree of response, the radiological
response lagging behind the clinical response. They argued
that residual parenchymal fibrotic density with associated
architectural distortion in the region of greatest initial
tumour volume and persisting unchanged 'malignant'
calcification were mainly responsible for the underestimation
of clinical response. In addition, they quantified minimal
response as a seperate parameter, as opposed to the present
study in which minimal responses were reported as stable
diseases, which may in part explain the lesser agreement in
clinical and radiological evaluation.
In conclusion, three cycles of FEC with dose-intensive
epidoxorubicin (FE,2oC) is clearly acceptable as an up-front
chemotherapy regimen in high-risk breast cancer patients.
High response rates are obtained, although the design of the
study does not allow any conclusions regarding the duration
of the response. FE,2oC appears to be well tolerated with
moderate bone marrow suppression as its major toxicity. As
far as the continued interest in developing combined modality
approaches in the treatment of high-risk breast cancer is
concerned, FE,20C seems to fulfill all the requirments for an
adequate up-front chemotherapy regimen. Following surgery,
a fourth course of FE120C to induce mobilisation of
autologous peripheral progenitor cells can successfully be
administered without additional toxicity.
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